Agoracom Blog Home

Posts Tagged ‘Psychedelic’

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:18 AM on Saturday, December 25th, 2021

The Roundup

A weekly summary of Novamind news and media

Dr. Steve Thayer with an important reminder that, for some, the holidays can be a difficult time of year for many reasons. He shares tips to care for our mental health and wellbeing over the holidays.

Watch on Instagram.

Novamind Signs Definitive Agreement to Acquire Arizona-based Clinics

We are pleased to announce the signing of a definitive agreement to acquire Arizona-based Foundations for Change, a mental health practice specialized in ketamine-assisted psychotherapy, from its sole stockholder, Jeff Edelman. The transaction is subject to regulatory approvals and is expected to close in January 2022.

Opened in 2017 by Jeff Edelman, Foundations currently operates one outpatient mental health clinic in Peoria, Arizona with an annual revenue run rate in excess of US$800,000 and owns a second, larger location in Phoenix that is scheduled to open in early 2022. Foundations will temporarily operate as “Foundations for Change by Novamind” until the Company completes its recently announced rebrand. Mr. Edelman will continue in a leadership capacity as Medical Director for both clinics. Mr. Edelman is double board-certified Family Psychiatric-Mental Health Nurse Practitioner and a Child and Adolescent Psychiatric-Mental Health Clinical Nurse Specialist. As a former military combat veteran, who served in the US Army 55th Medical Co. Combat Stress Control unit, Mr. Edelman has special expertise in treating military veterans and first responders who struggle with stress and trauma.

Read the full release here.

December 23, 2021

View all press releases

December 21, 2021

Horizons: Perspectives on Psychedelics Conference Recap

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison catch up after their recent trip to the “Horizons: Perspectives on Psychedelics” conference in New York. Stay tuned next week for our last episode of 2021 and a special PTF podcast contest and giveaway.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

With Health Care Workers Hurting, a Doctor Wants to See if a Psychedelic Can Help

NBC News reports on a first-of-its kind clinical trial at the University of Washington School of Medicine to treat 30 medical professionals experiencing depression with a dose of synthetic psilocybin combined with psychotherapy. Some say that even five years ago, this would have been considered taboo. “That medical researchers are turning toward psilocybin to treat colleagues is representative of a growing curiosity and acceptance of the drug among those in the medical establishment.” We’re seeing that openness, too, through our Frontline KAP clinical pilot to help healthcare workers heal.

Psychedelic-Assisted Therapy on the Rise in VA Hospitals

Lucid News covers how research partnerships exploring psychedelic-assisted psychotherapy as treatment option for veterans are gaining traction.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:58 AM on Saturday, December 18th, 2021

The Roundup

A weekly summary of Novamind news and media

December 14, 2021

Psychedelic Inspired Work Life Balance With Jeremiah Robison

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Jeremiah Robison to talk about work-life balance. Jeremiah is the Founder and CEO of Shroom Beach, a psychedelic-inspired clothing company that donates 10% of its profits to fund psychedelic medicine research

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

December 15, 2021

Doors Open in SLC

The announcement of our clinic launch in Salt Lake City is featured in Behavioral Health Executive and The Dales Report.
 
Both articles highlight how the new clinic will focus on treating substance use disorders and addiction-related illnesses led by incoming medical director Amy de la Garza.

View all media

Blossom Research Briefing: Eating Disorders

Blossom summarizes the exciting progress made on treating eating disorders with psychedelics. It’s a passion which our Chief Medical Officer, Dr. Reid Robison shares, working for years to bring innovative and effective treatment options to people suffering. Recently, Dr. Robison presented a keynote on the topic at the MindMed Australia International Summit on Psychedelic Therapies for Mental Illness. You can watch it here

Three Canadians With Mental Health Conditions Receive Legal Access to Psilocybin Mushrooms

Three more Canadians received legal access in a big win  that “opens it up to everyone,” but there are still issues with the system overall. “The process is still broken.” The Vancouver Sun explores how even with such positive news, there is still a lot of ground to cover in Therapsil’s fight for expanded access to psychedelic medicine. 

Across the World, COVID Anxiety and Depression Take Hold

No. We are not out of the woods. The Omicron variant is spreading quickly and with it, a slew of public health restrictions and fears reminiscent of March 2020. What can’t get lost in the shuffle again is addressing mental health. Especially for those on the frontlines of healthcare. “This sense of endlessness, accompanied by growing psychological distress leading to depression, was a recurrent theme in two dozen interviews conducted in Asia, Europe, Africa and the Americas. After two years of zigzagging policy and roller coaster emotions, terrible loss and tantalizing false dawns, closing borders and intermittently shuttered schools, people’s resilience has dwindled.” Frontline ketamine-assisted psychotherapy registration is still open for the next group of participants. Learn more here.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:08 AM on Saturday, December 11th, 2021

The Roundup

A weekly summary of Novamind news and media

Novamind Opens New Clinic with Specialized Focus on Substance Use Disorders

Salt Lake City Clinic welcomes incoming addictions specialist, Dr. Amy de la Garza

We are pleased to announce the opening of a new clinic located in downtown Salt Lake City (SLC). In addition to Novamind’s suite of mental health treatments, the SLC Clinic specializes in integrative behavioural health and services for adults with substance use disorders (SUD) led by incoming Medical Director, Dr. Amy de la Garza.

The SLC Clinic’s outpatient SUD services provide an alternative to residential treatment programs and work to address the highly complex public health crisis that is worsening alongside challenges related to access. In 2020 alone, 93,000 Americans died of a drug overdose-an increase of 30 per cent from the previous year, according to the Centers for Disease Control and Prevention.

Dr. Reid Robison, Novamind’s Chief Medical Officer, commented: “Social isolation and despair related to the COVID-19 pandemic have further fueled a significant increase in substance use disorders and related deaths. Dr. de la Garza’s expertise in addiction medicine and behavioural health is a vital addition to our team as we continue to expand Novamind’s clinic footprint to address unmet need and broaden our innovative, evidence-based treatments.”

Dr. de la Garza is a board-certified family practice physician with 10 years of experience providing specialized care for patients with behavioral health and SUD diagnoses. She earned her Doctorate in Medicine from the University of Colorado before completing a Family Medicine Residency at the Utah Healthcare Institute. She also completed an Addiction Medicine Fellowship at the University of Utah and is an Institute for Functional Medicine Certified Practitioner. In 2017, Dr. de la Garza opened the first community-based, co-located primary care and behavioral health practice in Salt Lake City, Utah.

“I am thrilled to join Novamind and look forward to establishing an innovative outpatient substance use disorder program that brings together addiction and integrative medicine and treats the whole person,” said Dr. de la Garza, who is also trained in integrative modalities and lifestyle medicine, including nutrition, movement, sleep, stress management and social connection.

Novamind will collect clinical data on the efficacy of the integrative treatment approach for SUD and host upcoming studies for conditions like opioid use disorder. Additionally, the SLC Clinic will pilot an innovative and cost-effective group medical visit model that has been shown to reduce anxiety and depression, as well as improve outcomes in chronic conditions like cardiovascular disease and diabetes.

The SLC Clinic is located at 807 E South Temple, Suite 101, Salt Lake City, Utah.

December 6, 2021

View all press releases

December 7, 2021

Anxiety: Why We Worry and What to Do About It

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore anxiety. They discuss the following topics and much more:
• What is an anxiety disorder?
• Anxiety management skills
• The role of medicines in treating anxiety

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

December 10, 2021

Ketamine-Assisted Therapy Is Having a Moment in Utah

Utah Business covers Dr. Reid Robison and the success of ketamine-assisted psychotherapy in our clinics. “While it’s still early and much more testing is to be done, Robison describes what’s happening in mental health care as a ‘psychedelic renaissance’.”

December 9, 2021

Doors Open in SLC

Benzinga covers the opening of our Salt Lake City clinic and future substance use disorder program led by Dr. Amy de la Garza.

December 9, 2021

Panel: International Summit on Psychedelic Therapies

Dr. Reid Robison, Matt Johnson and Robin Carhart-Harris discuss The Science of Psychedelics: Therapeutic mechanisms and clinical outcomes for a range of mental illnesses and other conditions.

December 8, 2021

Psychedelics & Eating Disorders

Chief Medical Officer Dr. Reid Robison’s keynote presentation at the Mind Medicine Australia International Summit on Psychedelic Therapies for Mental Illness.

View all media

Opioid Overdoses Are A Raging Public Health Crisis, Driven Mostly By Illicit Fentanyl And Heroin

“While the U.S. has been battling Covid-19 it’s gotten lost in the shuffle that the nation had record numbers of drug overdose-related deaths in 2020; approximately 93,000. In addition, from May 2020 through April 2021, the figure rises to 100,000.” We need better treatment options for people with substance use disorders (SUD). It’s the driving force behind why incoming Novamind Medical Director Dr. Amy de la Garza will lead SUD programming at our new Salt Lake City clinic.  

Psychedelics are Poised to Change the Course of Mental Health Treatment

We are currently in a mental health crisis. Depression, anxiety and symptoms of PTSD have run rampant over the last two years, accelerated by the COVID-19 pandemic and its far-reaching effects. The need for new and effective mental health treatments has never been clearer. We have seen the efficacy of ketamine-assisted psychotherapy firsthand. And we are eager to continue psychedelic research. If you’d like to stay up to date on upcoming studies hosted by Novamind, visit us here and get in touch. “So what else does the future hold for psychedelics? For one thing, taking psychedelics could one day be the same as taking an everyday pill prescribed by your doctor.”

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:19 AM on Saturday, December 4th, 2021

A weekly summary of Novamind news and media

Novamind Reports Fiscal Q1 Financial Results and Operating Highlights​

  • Multistate expansion underway, signed LOI to acquire Arizona-based mental health practice
  • Total revenue of $1,857,750, +113% when compared to same period last year
  • Total working capital of $6,834,011 to fund operations

“Q1 was a strong start to fiscal year 2022, driven by the addition of another clinic to our network and increased patient demand for our comprehensive range of innovative mental health treatments,” said Yaron Conforti, Novamind’s CEO and Director. “We continue to make progress on our national clinic expansion, most recently with a letter of intent to acquire two locations in Arizona. Our clinical research business has been actively building an exciting pipeline of contracts with leading drug developers.” 


Nov 29, 2021

Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America’s First Integrative Mental Health Clinic Network​

“Novamind operates best-in-class psychiatry clinics and clinical research sites, with a proven ability to replicate our clinic model in the U.S. Our agreement with Bienstar is an exciting opportunity to export our clinical expertise and capabilities into international markets,” said Yaron Conforti, Novamind CEO and Director. “Partnering with local operators allows us to disseminate Novamind’s best practices and SOPs globally, with minimal investment and managed risk, ultimately expanding access to psychedelic medicine and innovative mental healthcare on a global scale.”


Dec 1, 2021

Novamind to Present at the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6​

Novamind’s CEO and Director, Yaron Conforti, will join the Psychedelics Assisted Psychotherapy panel discussion from 1:30 PM to 2:15 PM EST. Mr. Conforti will also deliver a corporate presentation to update investors on recent milestones and progress towards the global expansion of Novamind’s psychedelic clinics and research sites.

For more information about the event and to register, visit https://hcwevents.com/psychedelics.


Dec 2, 2021

View all press releases

November 30, 2021

Taking the middle way in a polarized world​

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the concept of the “middle way” and the need for balance in an increasingly polarized world.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

Psychedelics Can Change Humanity for the Better. It’s Time to Unlock Their Power

In a piece for The Guardian, psychedelic pioneer Rick Doblin explains how psychedelics can change humanity for the better. “We envision a day when psychedelics will be more than a last-ditch treatment: they will be a catalyst for mass mental health.” 

The Promise and Pitfalls of Psychedelics

The work to destigmatize psychedelics has been long and arduous. Just ask Rick Doblin. He’s devoted his life to it. But as more and more research comes out, more and more people are changing their opinion on the once villainized substances. “Public attitudes around psychedelics are shifting: A recent Nanos Research survey, commissioned by the Canadian Psychedelic Association, found that 82 per cent of Canadians are in favour of psilocybin-assisted therapy in end-of-life illness, while 78 per cent of those polled support legalizing it to improve the quality of life for palliative and end-of-life patients.”

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:57 AM on Saturday, October 16th, 2021

A weekly summary of Novamind news and media, including the announcement we have been granted DEA licenses for psilocybin research.

October 12, 2021

Psychedelics, Mindfulness, and Contemplative Practices

In this episode of the podcast, Dr. Steve Thayer and Dr. Reid Robison are joined for the second time by Dr. Paul Thielking, MD. He is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. 

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

October 15, 2021

Why Palliative Care?

Chief Scientific Officer, Dr. Paul Thielking speaks with Amanda Siebert from The Dales Report on the potential of psychedelics for palliative care and the role of group therapy.

October 15, 2021

The Most Effective Pairing

In a recent interview with Technology Networks, Dr. Reid Robison spoke about the powerful combination of psychedelics and psychotherapy. 

October 14, 2021

A Key Step in Hosting Contracted Clinical Trials for Psilocybin Research

Chief Medical Officer, Dr. Reid Robison discusses Novamind being granted DEA licenses for psilocybin research and our new Psychedelic Palliative Care program with AGORACOM.

October 7, 2021

“We’re Just Scratching the Surface of What Can Be Done.”

Dr. Reid Robison opened the PSYCH Investor Summit with a keynote address presenting Novamind’s positioning and the rise and rollout of psychedelic medicine.

Don’t forget to download the third edition of PSYCH’s “The Psychedelics as Medicine Report”, featuring an expert interview with Dr. Robison.

View all media

Novamind Granted DEA Licenses for Psilocybin Research

We are pleased to announce we have been granted Schedule 1 licenses (the “DEA Licenses”) from the U.S. Drug Enforcement Agency (DEA) for Dr. Reid Robison, Chief Medical Officer, and Dr. Paul Thielking, Chief Scientific Officer. The DEA Licenses are required for research sites planning to host clinical trials for psilocybin, enabling principal investigators to store and administer this controlled substance.

“Obtaining the DEA Licenses is a critical step towards hosting clinical trials for psilocybin-assisted psychotherapy,” commented Dr. Robison. “We’re proud of our clinical research organization’s track record investigating innovative solutions for central nervous system conditions. This milestone reflects our expertise and enables us to continue on our mission to create breakthroughs in mental health treatment.”

Psilocybin has shown significant positive outcomes for people with major depressive disorder¹ and for reducing anxiety and depression in people with life-threatening cancer.² As of today, there are over 50 clinical studies actively examining the use of psilocybin, as listed on www.clinicaltrials.gov.

“The DEA Licenses are timely,” said Dr. Thielking, who last week launched Psychedelic Palliative Care by Novamind, a first of its kind program to support the mental health of patients and families struggling with serious illness. “We anticipate that this progress will accelerate the approval process for us to become a research site for additional psychedelic clinical studies in the future.”

To learn more about Novamind’s clinical research division, visit www.cedarclinicalresearch.com.

¹ https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630
² https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/

October 13, 2021

View all press releases

How COVID-19 Opened the Door to a New Era in Psychedelic Medicine

Time magazine writes how the burnout, trauma and stress caused by the COVID-19 pandemic is opening the door to accelerated psychedelic research. “It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care. The world is experiencing mass trauma from COVID-19.” It’s especially true with frontline workers. The stats are alarming. The need has never been more apparent. It’s why we launched our Frontline Ketamine-Assisted Psychotherapy treatment program earlier this year. We’re providing healthcare workers with critical mental healthcare. You can learn more about the program here.

Will Australia Take a Lead in Psychedelic Therapy?

Therapeutic Goods Administration (TGA) in Australia is currently evaluating a proposal to reschedule two prominent psychedelics into a less restrictive classification. Mind Medicine Australia submitted the proposal to the government and “has the support of world leading experts in psychedelic research.” 
Novamind Chief Medical Officer, Dr. Reid Robison, will be presenting at the Mind Medicine Australia summit in November. Get your tickets here.

The New Cannabis?

Could psychedelics follow the same path of cannabis toward legalization and regulation for medical purposes? It’s a question Luis Millán asks for National Magazine. “Despite the legal uncertainty, business is hopeful. Some stock market speculators believe psychedelics will follow in the footsteps of the cannabis industry and become the next billion-dollar business.”

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:56 AM on Saturday, October 9th, 2021

A weekly summary of Novamind news and media, including the launch of our new Psychedelic Palliative Care program.

October 5, 2021

Self Compassion, Forgiveness, and Judgment Detox

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss self-compassion, why it is so hard (but so important) to forgive, and how to detox from judgement.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

October 6, 2021

Novamind Today and Into the Future

CEO Yaron Conforti at the Benzinga Healthcare Small Cap Conference on the progress we’ve been making to increase access to psychedelic medicine.

October 6, 2021

Addressing Mental Health through Emerging Therapies Panel

CEO Yaron Conforti joins a panel of industry leaders at the Benzinga Healthcare Small Cap Conference for this informative discussion.

October 7, 2021

Dr. Reid Robison Keynote at PSYCH Investor Summit

Novamind’s Chief Medical Officer opened the Summit with a keynote drawing on his career as a pioneering psychiatrist and researcher in ketamine-assisted psychotherapy. Check back next week for footage of his presentation.

In addition, we are pleased to be featured in the third edition of PSYCH’s “The Psychedelics as Medicine Report”.

View all media

Novamind Launches New Psychedelic Palliative Care Program

We are pleased to launch Psychedelic Palliative Care by Novamind (the “Palliative Program”) at its recently opened clinic and research site in Murray, Utah.

Among the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness.

“Patients receiving palliative care have higher rates of depression than the general population. Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work,” explained Dr. Paul Thielking, Chief Scientific Officer (CSO) of Novamind. “Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies.”

Through Novamind’s clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin’s significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients.

Prior to his role as Novamind’s CSO, Dr. Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). He also pioneered an ongoing HCI study examining the feasibility of group-administered psilocybin-assisted psychotherapy for cancer patients experiencing depression. Dr. Thielking leads the Palliative Program’s multidisciplinary team of mental health professionals specialized in palliative care and psychedelic-assisted psychotherapy.

“Our healthcare system struggles to support the millions of Americans dealing with emotional, spiritual and psychological suffering associated with chronic or serious illness,” noted Dr. Thielking. “Psychedelic Palliative Care by Novamind is designed to address this need, bringing together fast-acting medicine, innovative treatment options and therapeutic expertise in a safe, nurturing environment.”

To learn more about the Palliative Program, visit www.novamind.ca/psychedelic-palliative-care

October 7, 2021

Novamind to Present at LD Micro and KCSA Conferences

We announced our participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.

Novamind’s CEO and Director, Yaron Conforti, will present our progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of our sixth clinic and the newly launched Psychedelic Palliative Care program.

Virtual LD Micro Main Event XIV
Date: October 13, 2021
Time: 10:30 AM to 11:00 AM EST
Register and watch live here: me21.mysequire.com

KCSA Psychedelics Virtual Investor Conference
Date: October 13, 2021
Time: 1:00 PM to 1:30 PM EST
Register and watch live here: www.virtualinvestorconferences.com/events/event-details/psychedelics-virtual-investor-conference

October 8, 2021

View all press releases

The Psychedelics Industry Could Offer a Whole New Approach to Work

In a collaboration with DoubleBlind magazine, Shelby Hartman and Madison Margolin explore how professional and economic systems are changing as the psychedelic revolution continues to grow. It’s not just about growth, though, but also the way we work. “What psychedelics offer is an invitation to look at professional and economic systems more, well, psychedelically.”

Psychedelics: Psychiatry of the Future

Covering Rick Doblin’s talk at the 2021 Annual Psychiatric Times World CME Conference, Leah Kuntz writes about what other conditions MDMA could treat including “depression, alcohol dependence, obsessive compulsive disorder, and even demoralization in AIDS survivors.” We look forward to further research on MDMA and will work to create treatment protocols for an array of mental health conditions, similar to our work with ketamine.

How Psychedelics are Returning to the World of Medicine

“According to estimates by the World Health Organization, about 300 million people worldwide live with depression.” It’s a stat that illuminates why there is so much urgency to bring psychedelic-assisted therapies to the world. We want to make a difference, to improve the quality of life for people suffering from depression and other mental health conditions, regardless of the psychedelic being used to bring about that lasting change. From Chief Medical Officer, Dr. Reid Robison: “I’m always touched by stories of hope and healing that come from witnessing the psychedelic modalities in action.”

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:29 AM on Saturday, October 2nd, 2021

A weekly summary of Novamind news and media, including the announcement of the opening of our 6ᵗʰ clinic in Murray, Utah.

September 28, 2021

Fear, Suffering, and the Value of Struggle

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss fear, the difference between pain vs. suffering, and the value of struggle in life.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

September 28, 2021

Dr. Reid Robison presents at the Life Sciences Investor Forum

In case you missed the presentation from our Chief Medical Officer, a recording of the presentation is now available for viewing here.

October 1, 2021

The Rapid Expansion Continues

Novamind CEO, Yaron Conforti, sits down with Agoracom to discuss opening our 6ᵗʰ clinic in Murray, UT and the broader vision for the company.

View all media

Novamind Opens 6ᵗʰ Integrative Psychiatry Clinic, Adds 3ʳᵈ Clinical Research Site

We are pleased to announce the opening of our sixth integrative psychiatry clinic. The clinic is in Murray, Utah (the “Murray Clinic”).

The Murray Clinic also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population. The Company anticipates 65,000 visits to its clinics this year.

“Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment,” explained Yaron Conforti, CEO and Director. “We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”

The Murray Clinic is the latest in Novamind’s ongoing clinic expansion, with two additional clinics slated to open in Utah by the end of 2021. The Salt Lake City location is scheduled to open in October, while the Park City location will open in November to accommodate the construction of the Company’s new flagship clinic design.

Learn more about Novamind’s clinical research division here.

September 30, 2021

View all press releases

How Psychedelics Changed my Life

The evidence continues to grow in support of psychedelic medicine. In a piece for the Independent, Jonathan Sabbagh writes about how psychedelics, and ketamine-assisted psychotherapy in particular, changed his life. “For the first time, I understood the truth. My burnout wasn’t an end in itself. It was a symptom of a previously undiagnosed severe case of post-traumatic stress disorder.”

The Science of Psychedelic Therapy Breaks on Through

Axios breaks down why psychedelics matter, where they stand and what to watch for in the future. “Scientific studies of psychedelic therapies may be entering a new, broader phase thanks to more interest and funding from federal governments.” We will continue to research psychedelics and other innovative therapies at Cedar Clinical Research. CCR’s research sites are co-located with Novamind’s Cedar Psychiatry clinics allowing for large client population recruitment and providing clients access to innovative research stage treatments. And just this last week, we announced the opening of a new research site and clinic.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

VIDEO – Novamind (NM : CSE) Opens 6th Integrative Psychiatry Clinic, Anticipates 65,000 Visits to Clinic Network This Year

Posted by AGORACOM-JC at 8:53 AM on Thursday, September 30th, 2021

Earlier today Novamind Inc. (NM : CSE) (NVMDF: OTCQB) (HN2: FSE) opened its sixth integrative psychiatry clinic. The “Murray Clinic” also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population.  

The Company anticipates 65,000 visits to its clinics this year. 

Yaron Conforti, CEO and Director, “Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment. We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.” 

Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.  

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:19 AM on Saturday, September 25th, 2021

A weekly summary of Novamind news and media, including the announcement of our inclusion in the NYSE Listed AdvisorShares Psychedelics ETF and more.

September 21, 2021

Burnout and the wounded healer​

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Paul Thielking. Paul is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. They discuss healthcare provider burnout and other unique challenges of being in the helping/healing professions.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF​

We are pleased to announce that we have been included in the AdvisorShares Psychedelics ETF trading on the NYSE under the ticker “PSIL” (the “ETF”).

PSIL is the first U.S.-listed, actively managed exchange traded fund to deliver dedicated investment exposure to psychedelics. PSIL seeks long-term capital appreciation by investing in the rapidly evolving psychedelics space, offering exposure to companies which the ETF’s portfolio manager views as leading the way in this nascent industry. The ETF currently includes 22 psychedelics companies. 

“The inclusion of Novamind in the AdvisorShares Psychedelics ETF is an important achievement for our Company,” commented Yaron Conforti, CEO and Director of Novamind. “Our clinics and clinical research sites are growing rapidly, and we are pleased to be recognized as a leading company in the emerging psychedelics sector.” 

Additional information on the ETF can be found here.

September 20, 2021

Novamind to Present at Benzinga Healthcare Conference​

Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare

We will participate in the Benzinga Healthcare Small Cap Conference taking place virtually on September 29-30, 2021.

Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.

Following the panel, from 1:15 PM to 1:30 PM EST, Mr. Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. A short Q&A session will follow.

For more information about the event and to register for free, visit: www.benzinga.com/events/small-cap/healthcare/

September 23, 2021

Novamind Announces DTC Eligibility for its Common Shares​

We are pleased to announce that our common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the U.S.

The DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered ‘DTC eligible’. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers. 

“We are pleased to have become DTC eligible. Investors will benefit from the accelerated settlement process and ability to trade Novamind shares through a wide range of U.S. brokerage firms,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “This is an important step towards increased liquidity for our stock and building a strong presence for Novamind in the U.S. capital markets.”

September 24, 2021

View all press releases

Mental Health, With a Side of Psychedelics?

A recap of some of the most promising psychedelic drugs for mental health and some of the trailblazers paving the way for the psychedelic revolution. “Sleep, exercise, therapy and antidepressants are some of the top remedies prescribed to assist the 1 in 4 Americans who struggle with mental health issues. But while these are all critical and effective tools, are they enough?”

Psychedelics Are a Billion-Dollar Business, and No One Can Agree Who Should Control It

Novamind’s business model was structured to be drug agnostic. We want to be able to provide the best possible therapies for our clients, regardless of what therapies they end up needing. It’s why we’re a champion for increasing access to all psychedelics. In this article, Shayla Love covers how those interested in psychedelics are learning to work together for the greater good. 

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

VIDEO – Delic Corp $DELC $DELCF Aims to Become “Largest Psychedelic Wellness Chain in the U.S.” via Ketamine Wellness Centers Acquisition $CMPS $ALID

Posted by AGORACOM-AB at 1:43 PM on Friday, September 24th, 2021

How much is the market for psychedelics going to be worth?

According to one report published earlier this year by Data Bridge Market Research, it will reach $6.9 billion by 2027. Another report, from Research and Markets, predicts it will go further, reaching $10.75 billion by 2027.

In addition: California legislators are considering decriminalizing possession and sharing of psychedelics for adults 21 and older.

That’s the market context you need to know for Delic Corp, which bills itself as a marketplace for the mainstream to access psychedelic wellness.

Delic owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms, including:

  • Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology
  • MeetDelic, the premiere psychedelic wellness event, which takes place in Las Vegas this year in November
  • and Ketamine Infusion Centers, one of the largest ketamine clinics in the United States

In May, Delic acquired Complex Biotech Discovery Ventures (CBDV), a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development, for $7m USD, changing its name to Delic Labs.

In June, Delic paid $3m USD to acquire Ketamine Infusion Centers, a limited liability corporation formed under the laws of Arizona, which owns and operates ketamine infusion treatment clinics in Phoenix, Arizona and in Bakersfield, California.

And now, Delic has this month entered into a binding merger with Ketamine Wellness Centers (KWC) Arizona, which operates 10 ketamine infusion treatment clinics across the U.S., in Arizona, Colorado, Florida, Illinois, Minnesota, Nevada Texas and Washington.

The deal and the national presence will bring psychedelic wellness treatment to the masses, and makes Delic the largest psychedelic wellness chain in the United States.

  • Retail Footprint to Include 12 Open Locations, with 15 Additional Clinics in Development
  • Ensures Accessibility to Millions with Affordable Treatments and Insurance Coverage
  • KWC has been operating profitably and expanding significantly with 2020 revenues in excess of $3.5m USD, on track for $4.5m USD in 2021
  • Joining Ketamine Infusion Centers (acquired June, 2021), which has grown steadily with revenues in excess of $4.2m USD since 2019

We sat down with Matt Stang, Delic’s CEO, to delve further into the acquisition…